E.coli LPS Antibody [M15H2]

Catalog No.: F1681

Application: Reactivity: Escherichia coli

Immunofluorescent analysis of Mouse liver tissue using F1681 (green, 1:200) and Hoechst (blue).

当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
IF1:200

Application
IF, ELISA

Source
Mouse Monoclonal Antibody

Reactivity
Escherichia coli

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

ポジティブコントロール	Mouse hepatocytes
ネガティブコントロール

プロトコール

IF
Experimental Protocol: Sample Preparation 1. Adherent Cells: Place a clean, sterile coverslip in a culture dish. Once the cells grow to near confluence as a monolayer, remove the coverslip for further use. 2. Suspension Cells: Seed the cells onto a clean, sterile slide coated with poly-L-lysine. 3. Frozen Sections: Allow the slide to thaw at room temperature. Wash it with pure water or PBS for 2 times, 3 minutes each time. 4. Paraffin Sections: Deparaffinization and rehydration. Wash the slide with pure water or PBS for 3 times, 3 minutes each time. Then perform antigen retrieval. Fixation 1. Fix the cell coverslips/spots or tissue sections at room temperature using a fixative such as 4% paraformaldehyde (4% PFA) for 10-15 minutes. 2. Wash the sample with PBS for 3 times, 3 minutes each time. Permeabilization 1.Add a detergent such as 0.1–0.3% Triton X-100 to the sample and incubate at room temperature for 10–20 minutes. (Note: This step is only required for intracellular antigens. For antigens expressed on the cell membrane, this step is unnecessary.) Wash the sample with PBS for 3 times, 3 minutes each time. Blocking Add blocking solution and incubate at room temperature for at least 1 hour. (Common blocking solutions include: serum from the same source as the secondary antibody, BSA, or goat serum.) Note: Ensure the sample remains moist during and after the blocking step to prevent drying, which can lead to high background. Immunofluorescence Staining (Day 1) 1. Remove the blocking solution and add the diluted primary antibody. 2. Incubate the sample in a humidified chamber at 4°C overnight. Immunofluorescence Staining (Day 2) 1. Remove the primary antibody and wash with PBST for 3 times, 5 minutes each time. 2. Add the diluted fluorescent secondary antibody and incubate in the dark at 4°C for 1–2 hours. 3. Remove the secondary antibody and wash with PBST for 3 times, 5 minutes each time. 4. Add diluted DAPI and incubate at room temperature in the dark for 5–10 minutes. 5. Wash with PBST for 3 times, 5 minutes each time. Mounting 1. Mount the sample with an anti-fade mounting medium. 2. Allow the slide to dry at room temperature overnight in the dark. 3. Store the slide in a slide storage box at 4°C, protected from light.

Experimental Protocol:

Sample Preparation

1. Adherent Cells: Place a clean, sterile coverslip in a culture dish. Once the cells grow to near confluence as a monolayer, remove the coverslip for further use.

2. Suspension Cells: Seed the cells onto a clean, sterile slide coated with poly-L-lysine.

3. Frozen Sections: Allow the slide to thaw at room temperature. Wash it with pure water or PBS for 2 times, 3 minutes each time.

4. Paraffin Sections: Deparaffinization and rehydration. Wash the slide with pure water or PBS for 3 times, 3 minutes each time. Then perform antigen retrieval.

Fixation

1. Fix the cell coverslips/spots or tissue sections at room temperature using a fixative such as 4% paraformaldehyde (4% PFA) for 10-15 minutes.

2. Wash the sample with PBS for 3 times, 3 minutes each time.

Permeabilization

1.Add a detergent such as 0.1–0.3% Triton X-100 to the sample and incubate at room temperature for 10–20 minutes.

(Note: This step is only required for intracellular antigens. For antigens expressed on the cell membrane, this step is unnecessary.)

Wash the sample with PBS for 3 times, 3 minutes each time.

Blocking

Add blocking solution and incubate at room temperature for at least 1 hour. (Common blocking solutions include: serum from the same source as the secondary antibody, BSA, or goat serum.)

Note: Ensure the sample remains moist during and after the blocking step to prevent drying, which can lead to high background.

Immunofluorescence Staining (Day 1)

1. Remove the blocking solution and add the diluted primary antibody.

2. Incubate the sample in a humidified chamber at 4°C overnight.

Immunofluorescence Staining (Day 2)

1. Remove the primary antibody and wash with PBST for 3 times, 5 minutes each time.

2. Add the diluted fluorescent secondary antibody and incubate in the dark at 4°C for 1–2 hours.

3. Remove the secondary antibody and wash with PBST for 3 times, 5 minutes each time.

4. Add diluted DAPI and incubate at room temperature in the dark for 5–10 minutes.

5. Wash with PBST for 3 times, 5 minutes each time.

Mounting

1. Mount the sample with an anti-fade mounting medium.

2. Allow the slide to dry at room temperature overnight in the dark.

3. Store the slide in a slide storage box at 4°C, protected from light.

Datasheet & SDS

生物学的記述

Specificity
E.coli LPS Antibody [M15H2] specifically detects E.coli LPS.

Clone
M15H2

Synonym(s)
Escherichia coli LPS

Background
E. coli LPS (Lipopolysaccharide) constitutes the primary structural component and potent endotoxin of the Gram-negative bacterial outer membrane, comprising Lipid A, core oligosaccharide, and O-antigen that collectively maintain membrane integrity while serving as the most powerful immunostimulatory molecule known. Lipid A anchors as a bis-phosphorylated β-1',6-glucosamine disaccharide acylated with six fatty acid chains forming the toxic moiety recognized by host TLR4-MD-2-CD14 receptor complex, while the core region links via Kdo-heptose sugars bearing charged phosphate/ethanolamine groups for membrane stabilization, and the highly variable O-antigen polysaccharide chain of repeating epitopes confers serotype specificity and immune evasion through phagocytosis/complement resistance creating "smooth" bacterial morphology. LPS forms an essential permeability barrier protecting against bile salts, antibiotics, and cationic peptides while triggering catastrophic innate immune activation through MyD88/TRIF-dependent NF-κB and IRF3 pathways driving massive TNF-α, IL-1β, IL-6 cytokine storms that precipitate septic shock, disseminated intravascular coagulation, and multi-organ failure during Gram-negative bacteremia; chronic low-grade endotoxemia from gut translocation contributes to atherosclerosis, neurodegenerative diseases, and metabolic syndrome via sustained vascular inflammation, positioning LPS as both indispensable bacterial structural element and humanity's most dangerous microbial toxin.

Background

E. coli LPS (Lipopolysaccharide) constitutes the primary structural component and potent endotoxin of the Gram-negative bacterial outer membrane, comprising Lipid A, core oligosaccharide, and O-antigen that collectively maintain membrane integrity while serving as the most powerful immunostimulatory molecule known. Lipid A anchors as a bis-phosphorylated β-1',6-glucosamine disaccharide acylated with six fatty acid chains forming the toxic moiety recognized by host TLR4-MD-2-CD14 receptor complex, while the core region links via Kdo-heptose sugars bearing charged phosphate/ethanolamine groups for membrane stabilization, and the highly variable O-antigen polysaccharide chain of repeating epitopes confers serotype specificity and immune evasion through phagocytosis/complement resistance creating "smooth" bacterial morphology. LPS forms an essential permeability barrier protecting against bile salts, antibiotics, and cationic peptides while triggering catastrophic innate immune activation through MyD88/TRIF-dependent NF-κB and IRF3 pathways driving massive TNF-α, IL-1β, IL-6 cytokine storms that precipitate septic shock, disseminated intravascular coagulation, and multi-organ failure during Gram-negative bacteremia; chronic low-grade endotoxemia from gut translocation contributes to atherosclerosis, neurodegenerative diseases, and metabolic syndrome via sustained vascular inflammation, positioning LPS as both indispensable bacterial structural element and humanity's most dangerous microbial toxin.

References
[1] Klein G, et al. J Biol Chem. 2013 Mar 22;288(12):8111-8127. [2] Bertani B, et al. EcoSal Plus. 2018 Aug;8(1):10.1128/ecosalplus.ESP-0001-2018.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%